Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin.
about
Protein Recognition in Drug-Induced DNA Alkylation: When the Moonlight Protein GAPDH Meets S23906-1/DNA Minor Groove AdductsTrypanocidal activity of marine natural productsManagement Strategies in Advanced Uterine Leiomyosarcoma: Focus on TrabectedinZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell linesMarine pharmacology in 2005-2006: antitumour and cytotoxic compounds.Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin.Trabectedin and its potential in the treatment of soft tissue sarcoma.Trabectedin for the management of soft-tissue sarcoma.New developments in treatment of ovarian carcinoma: focus on trabectedinLevels of active tyrosine kinase receptor determine the tumor response to ZalypsisTrabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma ModelsFEN1 promotes tumor progression and confers cisplatin resistance in non-small-cell lung cancer.Role of trabectedin in the treatment of soft tissue sarcomaDNA-Destabilizing Agents as an Alternative Approach for Targeting DNA: Mechanisms of Action and Cellular ConsequencesReplication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complexPM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity.Increased meiotic crossovers and reduced genome stability in absence of Schizosaccharomyces pombe Rad16 (XPF).Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancerBRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patientsA comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.BRCA2 is needed for both repair and cell cycle arrest in mammalian cells exposed to S23906, an anticancer monofunctional DNA binder.A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumorsIncreased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedinNew drugs and combinations for the treatment of soft-tissue sarcoma: a review.Statistics and outlook of primary hepatic angiosarcoma based on clinical stage.Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.Role of chemotherapy in the management of soft tissue sarcomas.Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomasNew therapies in soft tissue sarcoma.Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer.Clinical and pharmacokinetic evaluation of trabectedin for the treatment of soft-tissue sarcoma.Inhibiting homologous recombination for cancer therapy.Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics.ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.Unique features of trabectedin mechanism of action.Hallmarks of hyperthermia in driving the future of clinical hyperthermia as targeted therapy: translation into clinical application.
P2860
Q26778143-795D2DC3-C94D-4FAC-A590-471271F86F21Q27008593-9278EF2D-3C2F-445A-BB40-76D8B2DB66B7Q28087771-950AF732-353E-413D-90DE-53144D3D981AQ28476074-FCD84A3D-5CBC-4A9B-91AD-36165F1E4D31Q33359943-2D649551-17E5-49C2-9FFD-4CBD6150556EQ33377399-B7F89D52-E5E2-4113-81EA-13610C2E7969Q33380903-C16AD18C-F850-4870-8BB6-6310CE1957F9Q33384836-674004B8-C40D-433B-B407-81AAA5C8E66CQ33393429-104187B4-BA66-4617-BCA4-115FD9608591Q33622731-C57A8C8E-93AD-421C-9DE4-C5CBF8206BD3Q33649056-CE159C35-B45D-4054-ADE4-7BD7E2BD8DD5Q33787365-67C53049-4DA8-4E08-9921-CAE8DF3DA4F7Q33916011-52F2E578-94A4-4223-B26F-9D5526CE3297Q34042848-416E9E59-585B-4A01-B500-1CC7AE8D2ECDQ34581388-35D896D9-CDE3-4033-97CB-E48621B8C97AQ34594349-28B06BF3-16B5-47DA-803C-949FC580D9C9Q34624706-2E7C41EF-D007-4ED4-B058-6A78CA9E8935Q34636209-8D8B240D-28B6-43A5-8803-C16A5EC96CA0Q34650482-C72345D3-73A9-4F3B-AD5C-C36C2FA6F892Q34996149-8A2F9B6C-A133-44CF-802D-0AB7E5ACE9F2Q35098302-4E1ECB56-0427-408D-B599-A653FE5FC3D1Q35246995-17D80953-8FE8-4704-81DE-F6A93920EB95Q36188973-50C933EC-54CC-437D-ADB0-018338A35C93Q36233516-0FAA7041-895A-4BE2-B14D-7559C222CD56Q36432104-43C0FBB2-7A22-4A9F-A44F-8DE6838AC1FCQ36444369-81AFF456-7863-4519-8A35-9E2C3B9F0690Q36825289-772FE732-1FE7-43A1-B8A3-8355F87E5275Q37295535-08FB72CC-164F-42D8-8B70-356B2919EE7DQ37687389-D78F95DB-1975-4859-A794-54233107D387Q37747771-55BEDAAE-96D3-40D5-8B34-D1322287930EQ37750812-A413E3E3-7013-4F63-8D93-2A666C4DAB78Q37760957-DCA2B70F-0A6E-4786-8926-D0BE050B23C4Q37765581-7AF73D49-AE2D-40C9-84A4-28C693E1A1F6Q37969213-7805E172-55E8-4810-BC1E-47BB9093D16EQ37984197-127F3A7A-023A-48EA-BD07-66BDE88CD1CAQ38206366-AEC2D568-E19E-46F3-B528-C0F5F4735DAAQ38255906-052CAA0E-370A-40F3-834A-EE2494E0E1F8Q38337608-236B1AF2-39AF-4E01-8F73-CB567EB5CA21Q38669051-8DBFF8B8-2C41-49BA-9138-304433268E6AQ38709493-ED50A366-52DF-426B-B2C1-09300B3BC794
P2860
Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Cross-talk between nucleotide ...... tion of antitumor trabectedin.
@ast
Cross-talk between nucleotide ...... tion of antitumor trabectedin.
@en
Cross-talk between nucleotide ...... tion of antitumor trabectedin.
@nl
type
label
Cross-talk between nucleotide ...... tion of antitumor trabectedin.
@ast
Cross-talk between nucleotide ...... tion of antitumor trabectedin.
@en
Cross-talk between nucleotide ...... tion of antitumor trabectedin.
@nl
prefLabel
Cross-talk between nucleotide ...... tion of antitumor trabectedin.
@ast
Cross-talk between nucleotide ...... tion of antitumor trabectedin.
@en
Cross-talk between nucleotide ...... tion of antitumor trabectedin.
@nl
P2093
P1433
P1476
Cross-talk between nucleotide ...... tion of antitumor trabectedin.
@en
P2093
Ana B Herrero
Cristina Martín-Castellanos
Esther Marco
Sergio Moreno
P304
P356
10.1158/0008-5472.CAN-06-0179
P407
P577
2006-08-01T00:00:00Z